Therapeutic dilemma: crescentic mesangiocapillary glomerulonephritis type 1 in a patient on antituberculous therapy with rifampicin.
A
A
Kistler
D W
DW
Lappin
R A
RA
Coward
D000368:Aged; D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017291:Clarithromycin / Q000627:therapeutic use; D005260:Female; D015432:Glomerulonephritis, Membranoproliferative / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use*; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification; D011718:Pyrazinamide / Q000627:therapeutic use; D012293:Rifampin / Q000009:adverse effects*; D013183:Sputum / Q000382:microbiology; D014397:Tuberculosis, Pulmonary / Q000150:complications / Q000188:drug therapy*
D000995:Antitubercular Agents; D011718:Pyrazinamide; D017291:Clarithromycin; D007538:Isoniazid; D012293:Rifampin; D008775:Methylprednisolone